Todd M. Bertoch, MD

Chief Executive Officer
JBR Clinical Research
Salt Lake City, Utah

Presentation(s):

• Poster Number-49 - Selective Inhibition of NaV1.8 with VX-548 as a Targeted Treatment for Acute Pain

  Poster Abstracts